Hanmi Pharmaceutical posted record sales last year since its founding.
The local pharmaceutical company posted 1.3 trillion won in sales, a 73.1 percent increase from the previous year, alongside 211 billion won in operating profits and 162 billion won in net income, according to its regulatory filings on Thursday.
The strong sales came from the license fees with French multinational pharmaceutical company Sanofi and Belgium-based Janssen as well as sales from new products such as Rovelito, according to the firm.
Its investment in research and development stood at a total of 187 billion won as its project for the key new drug pipeline was transferred to a global partner company.
Although the investment volume rose by 22.7 percent, its investment rate compared to sales sharply rose to 14.2 percent.
The company's spokesperson said, "The company posted record sales thanks to the major license deals of its seven new drugs," adding, "We will continue this growth trend with continued R&D investment based on open innovation strategy."
